Harvard Licenses Genotyping Platform
News May 24, 2016
Harvard University has granted a license to Aldatu Biosciences Inc., an early-stage diagnostics development company, for a novel qPCR genotyping platform that may help clinicians treating HIV more quickly determine the most effective medication for each patient.
Developed at the Harvard T.H. Chan School of Public Health, the technology addresses the profound challenge of drug resistance among HIV-infected patients in resource-poor areas.
While potent antiretroviral (ARV) drugs exist to treat HIV infection, the virus is a constantly moving target, accumulating mutations and developing into strains that are resistant to a certain ARV, especially when a patient’s access to medication is interrupted or he or she does not adhere to a treatment regimen.
It is a costly and dangerous problem. The undetected presence of drug-resistant HIV strains in a population means that clinicians may be prescribing a medication that is in limited supply to patients on whom it is ineffective, and those patients may be unknowingly transmitting the resistant virus to others — for example, from mother to child during birth — compounding the problem.
“If you can identify resistance early and switch patients to the right drugs, you can reduce new infections,” said David Raiser, Ph.D. ’15, CEO of Aldatu.
The Cambridge-based startup is currently developing an HIV drug resistance genotyping test for patients failing first-line ARV therapy in low- and middle-income countries, where an inexpensive test could make a great difference across the health care system. Accordingly, the license from Harvard’s Office of Technology Development (OTD) is structured to maximize the global impact of the test; it grants Aldatu the right to implement the technology royalty-free in the developing world. Aldatu’s co-founders believe a test could be implemented within three years and could save millions of dollars in health care costs.
The licensed genotyping platform, called Pan Degenerate Amplification and Adaptation (PANDAA), was invented by two Harvard research associates: Iain MacLeod and Christopher Rowley, M.P.H. ’04, now assistant professor of medicine at Harvard Medical School and attending physician in the Department of Infectious Diseases at Beth Israel Deaconess Medical Center. MacLeod and Rowley were working in the lab of Myron (Max) Essex, the Mary Woodard Lasker Professor of Health Sciences at the Harvard Chan School and chair of the Botswana Harvard AIDS Institute Partnership (BHP).
The Essex lab specializes in studying HIV-1 viruses, the most common type of the disease, their interactions with the immune system, and molecular epidemiology — how the viruses change over time, affecting transmission, disease, and treatment. Through the BHP, a collaboration between the Harvard Chan School AIDS Initiative and the government of Botswana, Harvard researchers have been working for 20 years to stem the AIDS epidemic in southern Africa.
“Harvard has done phenomenal work in countries like Botswana and Uganda. A lot of the research, implementations, and policy decisions [around HIV] are actually driven by academia,” said MacLeod. “But a university doesn’t have the resources to reach every single infected individual.”
The OTD helped the members of the research team protect their intellectual property and advised them on the formation of a startup that could carry out a broader mission. Aldatu is incorporated as a public benefit corporation.
“In order to get the technology from its current state to a validated clinical diagnostic product,” said Raiser, “a company really needs to exist that has the explicit purpose of commercializing the technology and leveraging the market to get it to patients. OTD understood that, shared our values, and helped us get Aldatu up and running.”
The PANDAA project began in 2012 when Essex, MacLeod, and Rowley were contributing to a BHP study to assess rates of transmitted HIV drug resistance in recently infected pregnant women in Gaborone, Botswana.
With Rowley’s funding from the National Institutes of Health, the researchers were using existing commercial tests, “doing the genotyping themselves and experiencing firsthand the shortcomings of that technology,” said Raiser. During the study, they saw the rate of transmitted resistance creep up from about 1 percent in 2012 to close to 10 percent within a couple of years.
Simply studying, let alone solving, a problem of that magnitude was challenging. Using the older, real-time PCR tests, said MacLeod, “It takes 2½ days to look at eight samples, which is just not feasible for large populations.”
The process was relatively expensive, too. “The women participating [in the study] were exceptions to the rule; most women don’t have access to that type of testing,” Raiser explained. “This is something everyone should have access to, but the vast majority of people don’t because there aren’t better, faster, cheaper options that can be widely implemented.”
Essex, MacLeod, and Rowley set to work on inventing a better diagnostic platform. “We went through and really stressed this old system to see where we could build in some flexibility,” said MacLeod. “We just broke everything to see what works.”
To identify drug-resistant viruses, researchers look for key variations in the viral genome. The challenge is that HIV, like many pathogens, is highly polymorphic, meaning the genetic code is rife with slight variations called SNPs (“snips”). Some of these SNPs confer susceptibility or resistance to particular ARVs, while others play different roles in the genome. A highly sensitive technology like standard qPCR can turn up false negatives. PANDAA’s advantage, according to the inventors, is that it strips away distracting sequence variation while leaving the clinically relevant SNPs intact.
MacLeod and Raiser co-founded Aldatu in 2014, when Raiser was a doctoral student at Harvard Medical School and had recently completed a technology assessment fellowship in the OTD. The startup then joined the Harvard Innovation Labs’ Venture Incubation Program, and in 2014 it won the Bertarelli Foundation Grand Prize in the Harvard Deans’ Health and Life Sciences Challenge.
“That completely changed the way we were talking about Aldatu and HIV drug resistance,” said MacLeod. “It was a phenomenal learning experience.”
MacLeod and Raiser are now chief science officer and chief executive officer of Aldatu, respectively, and the company is based at LabCentral near Kendall Square. The license provides Aldatu exclusive rights to Harvard patents filed on PANDAA, covering application of the PANDAA technology in the fields of clinical diagnostics and in-vitro research. It also includes important global access provisions.
“The research team has been thoughtful about the economics of access to medical technology since it first came to us with this innovation,” said Grant Zimmermann, director of business development at the OTD. “We worked with Aldatu to license this technology under terms that would speed its path to the clinic in low-income countries, including providing a royalty-free license in the developing world that will help keep the cost as low as possible for the people who urgently need it.”
“We don’t want a big company replacing the current $300 test with another $300 test,” explained MacLeod. “A balance can be struck between being a for-profit company but one that also has a very public health-driven mission behind it. David and I are very strong-minded, if you will, about the public-benefit mission of Aldatu.”
In addition to the support from the Harvard Deans’ Health and Life Sciences Challenge, Aldatu has received seed funding from the National Institute of Allergy and Infectious Diseases and from private foundations.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
In a study of mice and human brain tumors researchers searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients’ tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation.READ MORE